Pomalidomide

證據等級: L5

預測適應症: 10 個

Pomalidomide: From Multiple Myeloma to Indolent Plasma Cell Myeloma

One-Sentence Summary

Pomalidomide is a second-generation immunomodulatory drug (IMiD) whose established use internationally is relapsed/refractory multiple myeloma; this is not captured as a structured field in the supplied dataset. The TxGNN model predicts activity in indolent plasma cell myeloma — a subtype within the same disease spectrum — supported by 1 completed clinical trial and 2 review publications currently identified.

Quick Overview

Item	Content
Original Indication	Not recorded in this dataset (`original_indications`/`original_moa` = data gap); externally known as multiple myeloma, relapsed/refractory
Predicted New Indication	Indolent plasma cell myeloma
TxGNN Prediction Score	93.96%
Evidence Level	L2
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Structured mechanism-of-action data is not available in this dataset (original_moa = data gap). Based on the supporting rationale accompanying this prediction (flagged explicitly as external pharmacological knowledge, not a local database field), pomalidomide is a cereblon (CRBN) E3 ubiquitin ligase modulator that drives degradation of IKZF1/IKZF3, giving it anti-angiogenic and immune-activating (T/NK cell) effects alongside TNF-α suppression.

Indolent plasma cell myeloma sits within the same disease spectrum as multiple myeloma — the malignancy pomalidomide is already used to treat internationally. This means the TxGNN prediction is best read as extending an established, on-target mechanism to a related disease stage/subtype, rather than proposing a genuinely novel therapeutic hypothesis. That narrows the uncertainty around biological plausibility, but it does not substitute for disease-specific trial evidence.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT02046915	Phase 2	Completed	60	Multicentre, single-arm study of pomalidomide + dexamethasone (with response-adapted cyclophosphamide) in relapsed/refractory myeloma; aimed to balance efficacy against the substantial risk of critical myelosuppression seen with alkylator-containing regimens.

No ANZCTR-registered trials were identified for this indication.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
22180161	2012	Review	American Journal of Hematology	2012 update on multiple myeloma diagnosis, risk-stratification and management.
21181954	2011	Review	American Journal of Hematology	2011 update on multiple myeloma diagnosis, risk-stratification and management; notes myeloma accounts for ~10% of haematologic malignancies.

Australia Market Information

Pomalidomide is currently not marketed in this dataset’s jurisdiction, with 0 ARTG-equivalent entries on file. No product listings, dosage forms, or approved indication text are available to summarise.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted/Immunomodulatory therapy (IMiD; not conventional cytotoxic chemotherapy)
Myelosuppression Risk	High — the completed Phase 2 trial (NCT02046915) explicitly flags patients as being at “substantial risk of critical myelosuppression”
Emetogenicity Classification	Please refer to the Product Information (PI) warnings and precautions
Monitoring Items	Full blood count (with differential) given documented myelosuppression risk; please refer to PI for full monitoring schedule
Handling Protection	Please refer to the Product Information (PI) and applicable hazardous-drug handling guidance

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. Key warnings, contraindications, and drug interaction data are not available in this dataset (drug interaction query returned “not found”).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A single completed Phase 2 trial (n=60) plus a mechanistically plausible extension of pomalidomide’s established myeloma-spectrum activity supports cautious progression, but a blocking safety-data gap and the drug’s current unmarketed status in this jurisdiction preclude a full “Go”.

To proceed, the following is needed:

TFDA/PI-sourced warnings and contraindications (flagged as a blocking gap — required before safety-stage evaluation can proceed)
Confirmed mechanism-of-action and DrugBank categorisation (currently a data gap)
Drug interaction data (current query status: not found)
An Australian regulatory pathway assessment, since the drug has zero ARTG-equivalent entries at present
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.